Synerkine Pharma Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Series 3

  • Latest Deal Amount
  • $12.9M

  • Investors
  • 6

Synerkine Pharma General Information

Description

Developer of fusion proteins designed to help in the treatment of inflammatory and neuropathic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has properties that normalize pain and inhibit inflammation, enabling patients to get access to pharmaceutical products that reduce pain in multiple pre-clinical models.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Galileiweg 8
  • 2333 BD Leiden
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Corporate Office
  • Galileiweg 8
  • 2333 BD Leiden
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Synerkine Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series 3) 03-Oct-2023 $12.9M Completed Pre-Clinical Trials
3. Early Stage VC (Series A2) 15-Dec-2021 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 25-Mar-2019 $3.74M $3.74M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jul-2018 Completed Startup
To view Synerkine Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Synerkine Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of fusion proteins designed to help in the treatment of inflammatory and neuropathic pain. The company's prote
Drug Discovery
Leiden, Netherlands
7 As of 2026

Allschwil, Switzerland
 

Ann Arbor, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Synerkine Pharma Competitors (4)

One of Synerkine Pharma’s 4 competitors is Bright Peak Therapeutics, a Venture Capital-Backed company based in Allschwil, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bright Peak Therapeutics Venture Capital-Backed Allschwil, Switzerland
Esperion Therapeutics Private Equity-Backed Ann Arbor, MI
Synthekine Venture Capital-Backed Menlo Park, CA
Corbus Pharmaceuticals Holdings Formerly VC-backed Norwood, MA
To view Synerkine Pharma’s complete competitors history, request access »

Synerkine Pharma Patents

Synerkine Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4612165-A1 Engineered immunocytokines, fusion polypeptides, and il10 polypeptides Pending 02-Nov-2022
WO-2024094755-A1 Engineered immunocytokines, fusion polypeptides, and il10 polypeptides Inactive 02-Nov-2022
AU-2020258026-A1 A fusion protein comprising il13 Inactive 19-Apr-2019
AU-2026214100-A1 A fusion protein comprising il13 Pending 19-Apr-2019
CA-3137058-A1 A fusion protein comprising il13 Active 19-Apr-2019 C07K14/5437
To view Synerkine Pharma’s complete patent history, request access »

Synerkine Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Synerkine Pharma Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
InnovationQuarter Venture Capital Minority
Utrecht Health Seed Fund Venture Capital Minority
Flerie Venture Capital Minority
Thuja Capital Management Venture Capital Minority
Utrecht Holdings Not-For-Profit Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Synerkine Pharma FAQs

  • When was Synerkine Pharma founded?

    Synerkine Pharma was founded in 2018.

  • Where is Synerkine Pharma headquartered?

    Synerkine Pharma is headquartered in Leiden, Netherlands.

  • What is the size of Synerkine Pharma?

    Synerkine Pharma has 7 total employees.

  • What industry is Synerkine Pharma in?

    Synerkine Pharma’s primary industry is Drug Discovery.

  • Is Synerkine Pharma a private or public company?

    Synerkine Pharma is a Private company.

  • What is Synerkine Pharma’s current revenue?

    The current revenue for Synerkine Pharma is .

  • How much funding has Synerkine Pharma raised over time?

    Synerkine Pharma has raised $20.6M.

  • Who are Synerkine Pharma’s investors?

    InnovationQuarter, Utrecht Health Seed Fund, Flerie, Thuja Capital Management, and Utrecht Holdings are 5 of 6 investors who have invested in Synerkine Pharma.

  • Who are Synerkine Pharma’s competitors?

    Bright Peak Therapeutics, Esperion Therapeutics, Synthekine, and Corbus Pharmaceuticals Holdings are competitors of Synerkine Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process